Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsEmpire Bluecross Avlayah Prior Auth Update | OpenP…
    Ask Trek AI about this page
    ModifiedEmpire BluecrossPolicy CC-0302

    Avlayah (tividenofusp alfa-eknm) Coverage Criteria

    Customize your policy alerts

    Sign up for Empire Bluecross Policy CC-0302 alerts

    Get alerted when Policy CC-0302 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medical-necessity and prior-authorization review for Avlayah in pediatric individuals with neurologic manifestations of Mucopolysaccharidosis II (Hunter syndrome), including initial and continuation therapy, quantity limits, and coding.

    Policy Summary
    PayerEmpire Bluecross
    PolicyAvlayah (tividenofusp alfa-eknm) Coverage Criteria
    Policy CodePolicy CC-0302
    Change TypeModified
    Effective DateJune 23, 2026
    Last ReviewMay 15, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation confirming pediatric age and weight, MPS II diagnosis, neurologic indication, and required clinical criteria.
    SourceLink
    POLICY UPDATE CHANGES

    HCPCS codes C9399 and J3590 were removed from the policy effective September 30, 2026.

    HCPCS code J1757 was added effective October 1, 2026 for injection of tividenofusp alfa-eknm.

    Under 18Initial therapy age requirement
    At least 5 kgInitial therapy minimum weight
    15 mg/kg weeklyAvlayah quantity limit
    J1757Current injection HCPCS code

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Elaprase combinationExplicit non-approval risk

    Coverage Criteria

    Initial Therapy

    Initial requests may be approved when ALL of the following are met:

    Initial Avlayah eligibility

    • MPS II diagnostic confirmation

      • Enzyme activity pathway: Deficiency in iduronate 2-sulfatase enzyme activity measured in fibroblasts or leukocytes, combined with a normal enzyme activity level of another sulfatase; documentation is provided.
      • Genetic pathway: A pathologic iduronate 2-sulfatase gene mutation is identified; documentation is provided.

    Continuation Therapy

    Continuation requests may be approved when the following criterion is met:

    Continuation response: Documentation is provided that there is clinically significant improvement or stabilization in clinical signs and symptoms of disease compared with the predicted natural history trajectory of disease.

    Examples include reduction in cerebrospinal fluid heparan sulfate and improvement in neurologic function; these examples are not exhaustive.

    Avlayah is not approved for use in combination with Elaprase.

    Avlayah is not approved when the stated approval criteria are not met or when it is requested for any other indication.

    Coding and Quantity Information

    HCPCSHCPCS
    J1757Injection, tividenofusp alfa-eknm, 1 mg [Avlayah]
    S9357Home infusion therapy, enzyme replacement intravenous therapy, (e.g., Imiglucerase); administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem
    ICD-10 DiagnosisICD-10
    E76.1Mucopolysaccharidosis, type II [Hunter's syndrome]
    Avlayah Dose and Quantity Limit
    DrugAvlayah (tividenofusp alfa-eknm)
    Strength150 mg vial
    Dose and quantity limit15 mg/kg once weekly

    Provider Actions and Review Requirements

    Prior Authorization

    Prior Authorization Required

    Avlayah is subject to clinical review, including prior authorization, under the member’s medical benefit plan. For an initial request, the individual must be younger than 18 years and weigh at least 5 kg.

    • Initial age requirement: less than 18 years
    • Initial weight requirement: at least 5 kg
    Documentation Required

    Diagnostic Confirmation

    Document the diagnosis of MPS II (Hunter syndrome) with required enzyme-activity or genetic testing evidence.

    • Deficiency in iduronate 2-sulfatase enzyme activity measured in fibroblasts or leukocytes, combined with normal activity of another sulfatase, with documentation provided; or
    • A pathologic iduronate 2-sulfatase gene mutation, with documentation provided

    Clinical Background

    Mucopolysaccharidosis II (MPS II), also known as Hunter syndrome, is an inherited metabolic disease caused by deficiency of lysosomal enzymes needed to break down glycosaminoglycans. Their progressive accumulation can produce neurologic and other multisystem complications. Avlayah (tividenofusp alfa-eknm) is an enzyme replacement therapy for eligible pediatric individuals with neurologic manifestations of MPS II; treatment is intended for use before advanced neurologic impairment and in individuals weighing at least 5 kg.

    Definitions

    Mucopolysaccharidosis II (MPS II; Hunter Syndrome)
    DiseaseMucopolysaccharidosis II (MPS II; Hunter syndrome)
    CauseDeficiency of the lysosomal enzyme iduronate 2-sulfatase
    Disease featuresProgressive accumulation of glycosaminoglycans with neurologic and other systemic complications
    Avlayah
    Generic nameTividenofusp alfa-eknm
    Therapy typeEnzyme replacement therapy
    Approved useTreatment of neurologic manifestations of MPS II in presymptomatic or symptomatic pediatric individuals weighing at least 5 kg before advanced neurologic impairment

    Initial Therapy Criteria

    Initial Therapy

    Initial requests may be approved if ALL of the following criteria are met:

    Initial Avlayah eligibility

    • MPS II diagnostic pathway

      • Enzyme activity pathway: Deficiency in iduronate 2-sulfatase enzyme activity as measured in fibroblasts or leukocytes combined with a normal enzyme activity level of another sulfatase, and documentation is provided.
      • Genetic pathway: A pathologic iduronate 2-sulfatase gene mutation is identified, and documentation is provided.

    Continuation Criteria

    Continuation Therapy

    Continuation requests may be approved when the following criterion is met:

    Clinically significant response or stabilization: Documentation is provided that there is clinically significant improvement or stabilization in clinical signs and symptoms of disease compared with the predicted natural history trajectory of disease.

    Documentation may include reduction in cerebrospinal fluid heparan sulfate or improvement in neurologic function.

    Quantity Limits

    Avlayah Quantity Limits
    ProductAvlayah (tividenofusp alfa-eknm)
    Vial strength150 mg vial
    Quantity limit15 mg/kg once weekly
    Policy Summary
    PayerEmpire Bluecross
    PolicyAvlayah (tividenofusp alfa-eknm) Coverage Criteria
    Policy CodePolicy CC-0302
    Change TypeModified
    Effective DateJune 23, 2026
    Last ReviewMay 15, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation confirming pediatric age and weight, MPS II diagnosis, neurologic indication, and required clinical criteria.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Quantity InformationProvider Actions and Review RequirementsClinical BackgroundDefinitionsInitial Therapy CriteriaContinuation CriteriaQuantity Limits
    Documentation Required

    Continuation Response Documentation

    For continuation requests, provide documentation showing clinically significant improvement or stabilization in disease signs and symptoms compared with the predicted natural history trajectory.

    • Examples include reduction in cerebrospinal fluid heparan sulfate (HS) or improvement in neurologic function
    Denial Risk

    Non-covered Use or Combination Therapy

    Avlayah may not be approved when the coverage criteria are not met, for use with Elaprase, or for indications other than those addressed by the policy.

    • Combination therapy with Elaprase is not approved
    • Initial or continuation criteria are unmet
    • All other indications are not approved
    Denial Risk

    Failure to Meet Initial Criteria

    Failure to satisfy any applicable initial criterion creates a denial risk for the request. Confirm the individual’s age, weight, diagnostic evidence, and requested indication before submission.

    • Individual must be less than 18 years of age
    • Individual must weigh at least 5 kg
    • MPS II diagnosis must be confirmed through the required enzyme-activity or pathologic gene-mutation documentation
    • The request must be for an addressed indication, including treatment of neurologic manifestations without advanced neurologic impairment